| Literature DB >> 33361087 |
Mohamed Lamkanfi1,2, Jo A Van Ginderachter3,4, Damya Laoui3,4, Máté Kiss5,4, Lieselotte Vande Walle1,2, Pedro H V Saavedra1,2, Els Lebegge5,4, Helena Van Damme5,4, Aleksandar Murgaski5,4, Junbin Qian6,7, Manuel Ehling8,9, Samantha Pretto8,9, Evangelia Bolli5,4, Jiri Keirsse5,4, Pauline M R Bardet5,4, Sana M Arnouk5,4, Yvon Elkrim5,4, Maryse Schmoetten5,4, Jan Brughmans5,4, Ayla Debraekeleer5,4, Amelie Fossoul1,2, Louis Boon10, Geert Raes5,4, Geert van Loo1,11, Diether Lambrechts6,7, Massimiliano Mazzone8,9, Alain Beschin5,4, Andy Wullaert1,2,11.
Abstract
IL1β is a central mediator of inflammation. Secretion of IL1β typically requires proteolytic maturation by the inflammasome and formation of membrane pores by gasdermin D (GSDMD). Emerging evidence suggests an important role for IL1β in promoting cancer progression in patients, but the underlying mechanisms are ill-defined. Here, we have shown a key role for IL1β in driving tumor progression in two distinct mouse tumor models. Notably, activation of the inflammasome, caspase-8, as well as the pore-forming proteins GSDMD and mixed lineage kinase domain-like protein in the host were dispensable for the release of intratumoral bioactive IL1β. Inflammasome-independent IL1β release promoted systemic neutrophil expansion and fostered accumulation of T-cell-suppressive neutrophils in the tumor. Moreover, IL1β was essential for neutrophil infiltration triggered by antiangiogenic therapy, thereby contributing to treatment-induced immunosuppression. Deletion of IL1β allowed intratumoral accumulation of CD8+ effector T cells that subsequently activated tumor-associated macrophages. Depletion of either CD8+ T cells or macrophages abolished tumor growth inhibition in IL1β-deficient mice, demonstrating a crucial role for CD8+ T-cell-macrophage cross-talk in the antitumor immune response. Overall, these results support a tumor-promoting role for IL1β through establishing an immunosuppressive microenvironment and show that inflammasome activation is not essential for release of this cytokine in tumors. ©2020 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33361087 DOI: 10.1158/2326-6066.CIR-20-0431
Source DB: PubMed Journal: Cancer Immunol Res ISSN: 2326-6066 Impact factor: 11.151